649 related articles for article (PubMed ID: 27012778)
1. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
Vaduganathan M; Bhatt DL; Cryer BL; Liu Y; Hsieh WH; Doros G; Cohen M; Lanas A; Schnitzer TJ; Shook TL; Lapuerta P; Goldsmith MA; Laine L; Cannon CP;
J Am Coll Cardiol; 2016 Apr; 67(14):1661-71. PubMed ID: 27012778
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.
Vaduganathan M; Cannon CP; Cryer BL; Liu Y; Hsieh WH; Doros G; Cohen M; Lanas A; Schnitzer TJ; Shook TL; Lapuerta P; Goldsmith MA; Laine L; Bhatt DL;
Am J Med; 2016 Sep; 129(9):1002-5. PubMed ID: 27143321
[TBL] [Abstract][Full Text] [Related]
3. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
[TBL] [Abstract][Full Text] [Related]
4. Clopidogrel with or without omeprazole in coronary artery disease.
Bhatt DL; Cryer BL; Contant CF; Cohen M; Lanas A; Schnitzer TJ; Shook TL; Lapuerta P; Goldsmith MA; Laine L; Scirica BM; Murphy SA; Cannon CP;
N Engl J Med; 2010 Nov; 363(20):1909-17. PubMed ID: 20925534
[TBL] [Abstract][Full Text] [Related]
5. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
[TBL] [Abstract][Full Text] [Related]
6. Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel.
Morneau KM; Reaves AB; Martin JB; Oliphant CS
J Manag Care Pharm; 2014 Feb; 20(2):187-93. PubMed ID: 24456320
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding.
Tsai YW; Wen YW; Huang WF; Chen PF; Kuo KN; Hsiao FY
J Gastroenterol; 2011 Jan; 46(1):39-45. PubMed ID: 20811753
[TBL] [Abstract][Full Text] [Related]
8. Individualised PPI prescription in patients on combination antiplatelet therapy and upper gastrointestinal events after percutaneous coronary intervention: a cohort study.
Häuptle R; Weilenmann D; Schneider T; Haile SR; Ammann P; Knellwolf C; Borovicka J
Wien Med Wochenschr; 2012 Feb; 162(3-4):67-73. PubMed ID: 22476595
[TBL] [Abstract][Full Text] [Related]
9. The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial.
Vardi M; Cryer BL; Cohen M; Lanas A; Schnitzer TJ; Lapuerta P; Goldsmith MA; Laine L; Doros G; Liu Y; McIntosh AI; Cannon CP; Bhatt DL
Aliment Pharmacol Ther; 2015 Aug; 42(3):365-74. PubMed ID: 26032114
[TBL] [Abstract][Full Text] [Related]
10. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
Gargiulo G; Costa F; Ariotti S; Biscaglia S; Campo G; Esposito G; Leonardi S; Vranckx P; Windecker S; Valgimigli M
Am Heart J; 2016 Apr; 174():95-102. PubMed ID: 26995375
[TBL] [Abstract][Full Text] [Related]
11. [Does dual antiplatelet therapy always require gastroprotection? Tailored medical therapy should prevail over the generalized prescription of proton pump inhibitors in patients on dual antiplatelet therapy].
Marcucci R
G Ital Cardiol (Rome); 2010 Jun; 11(6):481-7; discussion 487. PubMed ID: 20922874
[No Abstract] [Full Text] [Related]
12. Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
Chan FK; Kyaw M; Tanigawa T; Higuchi K; Fujimoto K; Cheong PK; Lee V; Kinoshita Y; Naito Y; Watanabe T; Ching JY; Lam K; Lo A; Chan H; Lui R; Tang RS; Sakata Y; Tse YK; Takeuchi T; Handa O; Nebiki H; Wu JC; Abe T; Mishiro T; Ng SC; Arakawa T
Gastroenterology; 2017 Jan; 152(1):105-110.e1. PubMed ID: 27641510
[TBL] [Abstract][Full Text] [Related]
13. Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial.
Burkard T; Kaiser CA; Brunner-La Rocca H; Osswald S; Pfisterer ME; Jeger RV;
J Intern Med; 2012 Mar; 271(3):257-63. PubMed ID: 21726302
[TBL] [Abstract][Full Text] [Related]
14. Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry.
Aihara H; Sato A; Takeyasu N; Nishina H; Hoshi T; Akiyama D; Kakefuda Y; Watabe H; Aonuma K;
Catheter Cardiovasc Interv; 2012 Oct; 80(4):556-63. PubMed ID: 22234956
[TBL] [Abstract][Full Text] [Related]
15. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study].
Yasu T; Ikee R; Miyasaka Y; Chubachi H; Saito S
Yakugaku Zasshi; 2010 Dec; 130(12):1743-50. PubMed ID: 21139402
[TBL] [Abstract][Full Text] [Related]
17. Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis.
Kwok CS; Nijjar RS; Loke YK
Drug Saf; 2011 Jan; 34(1):47-57. PubMed ID: 21047145
[TBL] [Abstract][Full Text] [Related]
18. Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights.
van Diepen S; Fuster V; Verma S; Hamza TH; Siami FS; Goodman SG; Farkouh ME
J Am Coll Cardiol; 2017 Jan; 69(2):119-127. PubMed ID: 28081820
[TBL] [Abstract][Full Text] [Related]
19. Rationale and Design for a Randomized Comparison of Efficacy and Safety between Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: CESAC-AF trial.
Park SM; Jeong H; Jung MH; Hong KS; Hong MK; Bang CS; Kim CY
Contemp Clin Trials; 2017 Sep; 60():51-55. PubMed ID: 28642210
[TBL] [Abstract][Full Text] [Related]
20. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
